SMAD4 and congenital rubella syndrome: Specifically, bone morphogenetic protein 6 (BMP6), Follistatin (FST), and tissue inhibitor of metalloproteinases 3 (TIMP3) (targets of miR-192-5p) were downregulated, while epidermal growth factor receptor (EGFR) and SMAD4 (targets of miR-146a-5p) were upregulated in CRS EV-treated group.